FDA's Questions and Answers on 21 CFR Part 11 for Clinical Investigations
Six Key Points
White Paper
Jul 18, 2019

We examine six of the more significant points from the draft guidance, specifically as they pertain to the eTMF, and offer insights on how this guidance provides justification for streamlining processes.

Contact Us
Contact Us

Email Us

Get in touch today to discover the right solutions for you.

Call Us

We are pleased to speak with you during our standard business hours.

U.S. Toll-Free only
+1 866 267 4479

For international call please find a number in our toll-free list.